T2 Biosystems, Inc. announced that its Board of Directors has appointed John Sperzel as President and Chief Executive Officer (CEO), effective January 8, 2020. Mr. Sperzel, who will also join the Board of Directors, succeeds John McDonough, who will continue with his Board leadership role serving as non-Executive Chairman. Mr. Sperzel brings a wealth of leadership and operating experience to T2 Biosystems. He most recently served as President and CEO of Chembio Diagnostics, Inc. from 2014 through 2020.

From September 2011 to December 2013, Mr. Sperzel was the Chief Executive Officer and President of International Technidyne Corporation, a developer of point-of-care cardiovascular diagnostic testing solutions. The Board appointed Mr. Sperzel as a Class II Director, to service on the Board until the 2022 Annual Meeting of Stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal.